Is the combination of mitomycin C, bleomycin and methotrexate effective as a neoadjuvant treatment for cervical cancer in women?

Objective: To determine the effectiveness of the combination of mitomycin C, bleomycin and methotrexate as a neoadjuvant treatment in preparation for surgical treatment of cervical cancer. Methods and materials: Twenty-seven patients with carcinoma of the uterine cervix (stages exophytic IB2 and IIB-IIIB) who had not previously undergone any treatment received mitomycin C, bleomycin and methotrexate in five sessions, once every four weeks. Results: The objective response rate was approximately 81%, including 16 complete responses and six partial responses. Significant toxic effects were not observed. Responsive patients underwent surgery and remained without evidence of disease for the next 20 years. Unresponsive patients did not fare well and passed away within five years after treatment. Conclusion: Our data suggest that this strategy may be effective for advanced cases, enabling patients to receive surgical treatment.

Bleomycin; Mitomycin; Methotrexate; Cervical cancer; Chemotherapy

[1] Sherris J., Herdman C., Elias C.: “Cervical cancer in the developing world”. West. J. Med., 2001, 175, 231.

[2] Perez C.A., Grigsby P.W., Chao K.S., Mutch D.G., Lockett M.A.: “Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix”. Int. J. Radiat. Oncol. Biol. Phys., 1998, 41, 307.

[3] Boruta D.M. 2nd, Schorge J.O., Duska L.A., Crum C.P., Castrillon

D. H., Sheets E.E.: “Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix”. Gynecol. Oncol., 2001, 81, 82.

[4] Pecorelli S., Odicino F.: “Cervical cancer staging“. Cancer J., 2003, 9, 390.

[5] Gray H.J.: “Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy”. J. Natl. Compr. Canc. Netw., 2008, 6, 47.

[6] Monk B.J., Tian C., Rose P.G., Lanciano R.: “Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials”. Gynecol. Oncol., 2007, 105, 427.

[7] Kim D.S., Moon H., Hwang Y.Y., Cho S.H.: “Preoperative adjuvant chemotherapy in the treatment of cervical cancer Stages Ib, IIa and IIb with bulky tumor”. Gynecol. Oncol., 1988, 29, 321.

[8] Muscato M.S., Perry M.C., Yarbso J.W.: “Chemotherapy of cervical carcinoma”. Semin. Oncol., 1982, 9, 373.

[9] Sismondi P., GiaiI M., Mano M.P., Cavalcanti T.C., Lamberto A.: “Tossicità midollare della chemioterapia nei tumori ginecologici”. Minerva Ginecol., 1985, 37, 27.

[10] Kokawa K., Nishimura R., Fujii T., Umesaki N.: “Neoadjuvant chemotherapy with irinotecan and mitomycin-C for locally advanced squamous cell carcinoma of the uterine cervix”. Anticancer Res., 2007, 27, 2721.

[11] Umezawa K., Nakazawa K., Uchihata Y., Otsuka M.: “Screening for inducers of apoptosis in apoptosis-resistant human carcinoma cells”. Adv. Enzyme Regul., 1999, 39, 145.

[12] Isonishi S., Terashima Y.: “Methotrexate in gynecologic oncology”. Gan To Kagaku Ryoho., 1996, 23, 1896.

[13] Chen J., Macdonald O.K., Gaffney D.K.: “Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix”. Obstet. Gynecol., 2008, 111, 1394.

[14] Tierney J.F., Vale C., Symonds P.: “Concomitant and neoadjuvant chemotherapy for cervical cancer”. Clin. Oncol. (R. Coll. Radiol.), 2008, 20, 401.

[15] Friedlander M.L., Atkinson K., Coppleson J.V.M., Elliot P., Green D., Houghton R. et al.: “The integration of chemotherapy into the management of locally advanced cervical cancer: a pilot study”. Gynecol. Oncol., 1984, 19, 1.

[16] Kim D.S., Moon H., Hwang Y.Y., Cho S.H.: “Preoperative adjuvant chemotherapy in the treatment of cervical cancer Stages Ib, IIa and IIb with bulky tumor”. Gynecol. Oncol., 1988, 29, 321.

[17] Rustin G.J.S., Newlands E.S., Southcott B., Singer A.: “Cisplatin, vincristine, methotrexate and bleomycin (POMB) as initial orpalliative chemotherapy for carcinoma of the cervix”. Br. J. Obstet. Gynaecol., 1987, 94, 1205.